Alterity Therapeutics Limited (ATHE) has a negative trailing P/E of -6.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -15.93%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -7.3 | -0.31 | 1.80 | 396.57 | - |
| 2017 | -3.5 | 1.27 | 1.12 | 199.87 | - |
| 2018 | -2.7 | -0.28 | 1.41 | 112.74 | - |
| 2019 | -1.6 | -0.06 | 1.14 | 173.72 | - |
| 2020 | -2.6 | 0.06 | 2.44 | 0.00 | - |
| 2021 | -3.2 | 0.19 | 1.61 | 11.29 | - |
| 2022 | -2.8 | 0.07 | 1.00 | 6.91 | - |
| 2023 | -1.2 | -0.16 | 0.74 | 4.33 | - |
| 2024 | -0.9 | 0.10 | 1.19 | 4.09 | - |
| 2025 | -5.5 | 0.09 | 1.56 | 12.18 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-8.70 | $142.66K | $-7.73M | -5418.3% |
| 2017 | $-8.46 | $132.4K | $-7.54M | -5696.6% |
| 2018 | $-9.30 | $201.17K | $-8.27M | -4108.8% |
| 2019 | $-11.64 | $108.54K | $-11.96M | -11020.8% |
| 2020 | $-6.48 | $0.00 | $-9.7M | - |
| 2021 | $-5.40 | $4.34M | $-15.31M | -352.8% |
| 2022 | $-3.18 | $5.12M | $-12.85M | -250.7% |
| 2023 | $-3.42 | $3.92M | $-13.81M | -352.5% |
| 2024 | $-3.12 | $4.02M | $-19.12M | -475.8% |
| 2025 | $-1.14 | $5.44M | $-12.15M | -223.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.10 | $-0.10 – $-0.10 | $6M | $6M – $6M | 1 |
| 2027 | $-0.07 | $-0.14 – $0.00 | $4.2M | $4.2M – $4.2M | 2 |
| 2028 | $-0.06 | $-0.06 – $-0.06 | $11.47M | $11.47M – $11.47M | 1 |
| 2029 | $-0.05 | $-0.05 – $-0.05 | $17.86M | $17.86M – $17.86M | 1 |
| 2030 | $-0.11 | $-0.11 – $-0.11 | $6.18M | $6.18M – $6.18M | 1 |
